{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:13:06Z","timestamp":1784077986186,"version":"3.55.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["53234351"],"award-info":[{"award-number":["53234351"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Vancomycin remains the treatment-of-choice in MRSA bacteraemia (MRSAB) despite significant limitations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To compare the effectiveness of ceftaroline and vancomycin monotherapy as the initial targeted therapy for MRSAB.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective matched cohort study. Consecutive adult patients treated with ceftaroline in the years 2019\u20132021 were matched in a 1:2 ratio with patients who received vancomycin. Controls were matched for performance of trans-oesophageal echocardiography, Charlson comorbidity index and age. The primary outcome was a composite of treatment failure, defined as 90-day mortality or microbiological failure. Descriptive statistics were used to compare the ceftaroline and vancomycin-treated groups. Univariate and multivariable binary logistic regression models were created using ceftaroline treatment as the exposure variable.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty-five patients treated with ceftaroline for MRSAB were matched with 83 patients who received vancomycin. The groups were well balanced with regards to demographics and clinical characteristics. The primary outcome of treatment failure occurred at a similar rate in patients treated with ceftaroline or vancomycin (51.1%, 23\/45% versus 57.8%, 48\/83, respectively, P\u200a=\u200a0.47). In the multivariable analysis, only age (aOR 1.06, 95% CI 1.01\u20131.1, P\u200a=\u200a0.02) was associated with treatment failure. Acute kidney injury was more common among patients treated with ceftaroline (51.1%, 23\/45% versus 18.1%, 15\/83, P\u200a&amp;lt;\u200a0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ceftaroline was not associated with improved outcomes compared to vancomycin when given as initial treatment for MRSAB, however, it appears to be a viable alternative to vancomycin. Larger studies are needed to provide definitive results and to elucidate the risk of nephrotoxicity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf009","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T08:05:08Z","timestamp":1738051508000},"page":"848-856","source":"Crossref","is-referenced-by-count":4,"title":["Ceftaroline versus vancomycin for methicillin-resistant <i>Staphylococcus aureus<\/i> bacteraemia, a matched cohort study"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7495-3398","authenticated-orcid":false,"given":"Roni","family":"Bitterman","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Rambam Health Care Campus , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Awwad","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Technion-Israeli Institute of Technology , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basel","family":"Darawsha","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Technion-Israeli Institute of Technology , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajar","family":"Dallashi","sequence":"additional","affiliation":[{"name":"Internal Medicine B, Rambam Health Care Campus , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Dishon-Benattar","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Rambam Health Care Campus , Haifa ,","place":["Israel"]},{"name":"The Cheryl Spencer Department of Nursing, University of Haifa , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Pollack","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Technion-Israeli Institute of Technology , Haifa ,","place":["Israel"]},{"name":"Microbiology Laboratory, Rambam Health Care Campus , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2317-1112","authenticated-orcid":false,"given":"Mical","family":"Paul","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Rambam Health Care Campus , Haifa ,","place":["Israel"]},{"name":"Faculty of Medicine, Technion-Israeli Institute of Technology , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"2025030423054531200_dkaf009-B1","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/INF.0000000000001160","article-title":"A multicenter, randomized, observer-blinded, active-controlled study evaluating the safety and effectiveness of ceftaroline compared with ceftriaxone plus vancomycin in pediatric patients with complicated community-acquired bacterial pneumonia","volume":"35","author":"Blumer","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2025030423054531200_dkaf009-B2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/INF.0000000000001159","article-title":"A randomized, prospective study of pediatric patients with community-acquired pneumonia treated with ceftaroline versus ceftriaxone","volume":"35","author":"Cannavino","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2025030423054531200_dkaf009-B3","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1086\/657313","article-title":"Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia","volume":"51","author":"File","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"2025030423054531200_dkaf009-B4","doi-asserted-by":"publisher","first-page":"iii19","DOI":"10.1093\/jac\/dkr096","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054531200_dkaf009-B5","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1097\/INF.0000000000001191","article-title":"A multicenter, randomized, observer-blinded, active-controlled study to evaluate the safety and efficacy of ceftaroline versus comparator in pediatric patients with acute bacterial skin and skin structure infection","volume":"35","author":"Korczowski","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 3","key":"2025030423054531200_dkaf009-B6","doi-asserted-by":"publisher","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054531200_dkaf009-B7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1473-3099(14)71018-7","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial","volume":"15","author":"Zhong","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 4","key":"2025030423054531200_dkaf009-B8","doi-asserted-by":"publisher","first-page":"iv53","DOI":"10.1093\/jac\/dkq255","article-title":"CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054531200_dkaf009-B9","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1093\/jac\/dkw333","article-title":"A phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities","volume":"71","author":"Dryden","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 4","key":"2025030423054531200_dkaf009-B10","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/jac\/dkq254","article-title":"CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054531200_dkaf009-B11","author":"FDA"},{"key":"2025030423054531200_dkaf009-B12","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1016\/j.ijid.2012.02.009","article-title":"Healthcare-associated vs. hospital-acquired Staphylococcus aureus bacteremia","volume":"16","author":"Bishara","year":"2012","journal-title":"Int J Infect Dis"},{"key":"2025030423054531200_dkaf009-B13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4065\/mcp.2010.0705","article-title":"Thrombocytopenia in Staphylococcus aureus bacteremia: risk factors and prognostic importance","volume":"86","author":"Gafter-Gvili","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"2025030423054531200_dkaf009-B14","doi-asserted-by":"publisher","first-page":"h2219","DOI":"10.1136\/bmj.h2219","article-title":"Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial","volume":"350","author":"Paul","year":"2015","journal-title":"BMJ"},{"key":"2025030423054531200_dkaf009-B15","doi-asserted-by":"publisher","first-page":"e008838","DOI":"10.1136\/bmjopen-2015-008838","article-title":"External validity of a randomised controlled trial on the treatment of severe infections caused by MRSA","volume":"5","author":"Paul","year":"2015","journal-title":"BMJ Open"},{"key":"2025030423054531200_dkaf009-B16","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1093\/jac\/dkq373","article-title":"Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia","volume":"65","author":"Paul","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054531200_dkaf009-B17","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/j.1469-0691.2010.03425.x","article-title":"Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?","volume":"17","author":"Paul","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2025030423054531200_dkaf009-B18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s15010-016-0919-6","article-title":"Time trends in Staphylococcus aureus bacteremia, 1988-2010, in a tertiary center with high methicillin resistance rates","volume":"45","author":"Yahav","year":"2017","journal-title":"Infection"},{"key":"2025030423054531200_dkaf009-B19","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10096-016-2598-8","article-title":"Risk factors for long-term mortality of Staphylococcus aureus bacteremia","volume":"35","author":"Yahav","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025030423054531200_dkaf009-B20","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.cmi.2022.03.015","article-title":"Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis","volume":"28","author":"Bai","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2025030423054531200_dkaf009-B21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2025030423054531200_dkaf009-B22","doi-asserted-by":"publisher","first-page":"ofy042","DOI":"10.1093\/ofid\/ofy042","article-title":"Influence of reported penicillin allergy on mortality in MSSA bacteremia","volume":"5","author":"Turner","year":"2018","journal-title":"Open forum Infect Dis"},{"key":"2025030423054531200_dkaf009-B23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1086\/510386","article-title":"Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia","volume":"44","author":"Stryjewski","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2025030423054531200_dkaf009-B24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2025030423054531200_dkaf009-B25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/cid\/civ235","article-title":"Predicting risk of endocarditis using a clinical tool (PREDICT): scoring system to guide use of echocardiography in the management of Staphylococcus aureus bacteremia","volume":"61","author":"Palraj","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025030423054531200_dkaf009-B26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.cmi.2016.10.023","article-title":"Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition","volume":"23","author":"Harris","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2025030423054531200_dkaf009-B27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00134-006-0478-x","article-title":"Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria","volume":"33","author":"Bellomo","year":"2007","journal-title":"Intensive Care Med"},{"key":"2025030423054531200_dkaf009-B28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction\/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"2025030423054531200_dkaf009-B29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/archinte.1962.03620240029006","article-title":"Gram-negative bacteremia. I. Etiology and ecology","volume":"110","author":"McCabe","year":"1962","journal-title":"Arch Intern Med"},{"key":"2025030423054531200_dkaf009-B30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijid.2017.01.019","article-title":"Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study","volume":"57","author":"Arshad","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2025030423054531200_dkaf009-B31","doi-asserted-by":"publisher","first-page":"ofab606","DOI":"10.1093\/ofid\/ofab606","article-title":"Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant Staphylococcus aureus bloodstream infection","volume":"9","author":"Zasowski","year":"2021","journal-title":"Open forum Infect Dis"},{"key":"2025030423054531200_dkaf009-B32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40801-024-00422-5","article-title":"Ceftaroline fosamil for the treatment of methicillin-resistant Staphylococcus aureus bacteremia: a real-world comparative clinical outcomes study","volume":"11","author":"Hammond","year":"2024","journal-title":"Drugs Real World Outcomes"},{"key":"2025030423054531200_dkaf009-B33","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1056\/NEJMoa2300220","article-title":"Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia","volume":"389","author":"Holland","year":"2023","journal-title":"N Engl J Med"},{"key":"2025030423054531200_dkaf009-B34","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1086\/655827","article-title":"Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection","volume":"51","author":"Corey","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"Suppl 4","key":"2025030423054531200_dkaf009-B35","doi-asserted-by":"publisher","first-page":"iv67","DOI":"10.1093\/jac\/dkq256","article-title":"Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corrado","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054531200_dkaf009-B36","doi-asserted-by":"publisher","first-page":"106310","DOI":"10.1016\/j.ijantimicag.2021.106310","article-title":"Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care","volume":"57","author":"Johnson","year":"2021","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/3\/848\/61658546\/dkaf009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/3\/848\/61658546\/dkaf009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:05:58Z","timestamp":1741129558000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/3\/848\/7985145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,28]]},"published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf009","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,1,28]]}}}